Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Catalyst Pharmaceuticals, Inc. - Common Stock (NQ:CPRX)

31.50 +0.05 (+0.16%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 6, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	921,748
Open	31.45
Bid (Size)	31.47 (200)
Ask (Size)	31.50 (4,900)
Prev. Close	31.45
Today's Range	31.45 - 31.50
52wk Range	19.05 - 32.56
Shares Outstanding	102,780,151
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Deep Value Play with Rare Disease Pipeline Strength ↗

July 02, 2026

Via Chartmill

Vamorolone Demonstrates On-Target Glucocorticoid Activity Without the Immunosuppression Characteristic of Traditional Corticosteroids at Clinical Doses

June 30, 2026

Data Demonstrate Vamorolone’s Balanced Corticosteroid Profile with On-Target Glucocorticoid Activity and Without Evidence of Significant Immunosuppressive Activity at Clinical Doses

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

Performance

YTD	+36.1%	+36.1%
1 Month	+0.7%	+0.7%
3 Month	+26.1%	+26.1%
6 Month	+38.2%	+38.2%
1 Year	+50.4%	+50.4%

More News

Catalyst Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalyst Pharmaceuticals, Inc. - CPRX

June 24, 2026

From Kahn Swick & Foti, LLC

Via Business Wire

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Passes "Caviar Cruise" Quality Screen with Zero Debt and 147.5% ROIC ↗

June 24, 2026

Via Chartmill

Catalyst Pharmaceuticals (NASDAQ:CPRX) Shows Strong Growth and a Bullish Technical Setup ↗

May 26, 2026

Via Chartmill

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Scores 7/10 Fundamental Rating in Affordable Growth Screen ↗

May 11, 2026

Via Chartmill

Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) Presents a Compelling Value Investment Case ↗

April 18, 2026

Via Chartmill

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Stands Out as a Quality Investment ↗

March 21, 2026

Via Chartmill

GlobeFlex Exits NCR Atleos After Brink’s Buyout Deal ↗

May 20, 2026

Via The Motley Fool

Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results

May 11, 2026

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

Catalyst Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalyst Pharmaceuticals, Inc. - CPRX

May 09, 2026

From Kahn Swick & Foti, LLC

Via Business Wire

Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) Presents a Compelling Value Investment Case ↗

March 11, 2026

Via Chartmill

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Strong Fundamental and Technical Setup ↗

March 05, 2026

Via Chartmill

Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) Shows Technical Setup for Potential Breakout ↗

February 26, 2026

Via Chartmill

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Beats Q4 Estimates, Issues Conservative 2026 Outlook ↗

February 25, 2026

Via Chartmill

This Biotech Stock Has Soared 175%. Here’s Why One Fund Still Sold $3 Million Worth ↗

May 09, 2026

Via The Motley Fool

Catalyst Pharmaceuticals Cancels First Quarter 2026 Conference Call and Webcast

May 07, 2026

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

CPRX Stock Alert: Halper Sadeh LLC is Investigating Whether Catalyst Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders

May 07, 2026

From Halper Sadeh LLC

Via Business Wire

Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), Entering the U.S. Market and Consolidating its Leadership in Brain Health and Rare Disease

May 07, 2026

From Angelini Pharma; Catalyst Pharmaceuticals

Via GlobeNewswire

Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Hetero Labs Ltd.

May 07, 2026

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

Catalyst Pharmaceuticals to Report First Quarter 2026 Financial Results on May 11, 2026

April 28, 2026

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Strong Growth Stock with a Positive Technical Setup ↗

April 14, 2026

Via Chartmill

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Emerges as a Top Affordable Growth Stock ↗

April 10, 2026

Via Chartmill

Catalyst Pharmaceuticals to Showcase Real‑World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific Conference

March 06, 2026

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance

February 25, 2026

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Catalyst Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, Catalyst Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does Catalyst Pharmaceuticals, Inc. - Common Stock trade on?

Catalyst Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Catalyst Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for Catalyst Pharmaceuticals, Inc. - Common Stock is CPRX on the Nasdaq Stock Market

What is the current price of Catalyst Pharmaceuticals, Inc. - Common Stock?

The current price of Catalyst Pharmaceuticals, Inc. - Common Stock is 31.50

When was Catalyst Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of Catalyst Pharmaceuticals, Inc. - Common Stock was at 07/06/26 04:00 PM ET

What is the market capitalization of Catalyst Pharmaceuticals, Inc. - Common Stock?

The market capitalization of Catalyst Pharmaceuticals, Inc. - Common Stock is 3.24B

How many shares of Catalyst Pharmaceuticals, Inc. - Common Stock are outstanding?

Catalyst Pharmaceuticals, Inc. - Common Stock has 3B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.